Cargando…
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
BACKGROUND: Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to...
Autores principales: | Nojomi, Marzieh, Yassin, Zeynab, Keyvani, Hossein, Makiani, Mahin Jamshidi, Roham, Maryam, Laali, Azadeh, Dehghan, Nasir, Navaei, Mehrnaz, Ranjbar, Mitra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734453/ https://www.ncbi.nlm.nih.gov/pubmed/33317461 http://dx.doi.org/10.1186/s12879-020-05698-w |
Ejemplares similares
-
Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
por: Amani, Behnam, et al.
Publicado: (2021) -
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
por: Haviernik, Jan, et al.
Publicado: (2018) -
Antiviral drug Umifenovir (Arbidol) in municipal wastewater during the COVID-19 pandemic: Estimated levels and transformation
por: Ul'yanovskii, Nikolay V., et al.
Publicado: (2022) -
Effect of umifenovir (arbidol) versus standard care
on clinical outcome in patients with COVID-19: a retrospective cohort
study
por: Yi, Wanwan, et al.
Publicado: (2023) -
SARS-CoV-2 Molecular and Phylogenetic analysis in COVID-19 patients: A preliminary report from Iran
por: Tabibzadeh, Alireza, et al.
Publicado: (2020)